keyword
MENU ▼
Read by QxMD icon Read
search

Rifaximin

keyword
https://www.readbyqxmd.com/read/29052858/editorial-rifaximin-in-cirrhosis-is-it-what-we-ve-been-waiting-for
#1
EDITORIAL
J Huang
No abstract text is available yet for this article.
November 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29052857/editorial-rifaximin-in-cirrhosis-is-this-what-we-ve-been-waiting-for-authors-reply
#2
EDITORIAL
S H Kang, Y B Lee, J-H Lee
No abstract text is available yet for this article.
November 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29029033/trial-evaluating-ambulatory-therapy-of-travelers-diarrhea-treat-td-study-a-randomized-controlled-trial-comparing-3-single-dose-antibiotic-regimens-with-loperamide
#3
Mark S Riddle, Patrick Connor, Jamie Fraser, Chad K Porter, Brett Swierczewski, Emma J Hutley, Brook Danboise, Mark P Simons, Christine Hulseberg, Tahaniyat Lalani, Ramiro L Gutierrez, David R Tribble
Background: Recommended treatment for travelers' diarrhea includes the combination of an antibiotic, usually a fluoroquinolone or azithromycin, and loperamide for rapid resolution of symptoms. However, adverse events, postdose nausea with high-dose azithromycin, effectiveness of single-dose rifaximin, and emerging resistance to front-line agents are evidence gaps underlying current recommendations. Methods: A randomized, double-blind trial was conducted in 4 countries (Afghanistan, Djibouti, Kenya, and Honduras) between September 2012 and July 2015...
September 23, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29026340/economic-impact-of-the-use-of-rifaximin-550-mg-twice-daily-for-the-treatment-of-overt-hepatic-encephalopathy-in-italy
#4
Daniela Paola Roggeri, Alessandro Roggeri
PURPOSE: Hepatic encephalopathy (HE) is associated with a reduced survival, an increased risk of hospitalization for recurrences, and a reduced health-related quality of life. The purpose of the present economic analysis was to evaluate the impact on the Italian National Health Service (INHS) expenditure of the treatment with rifaximin 550 mg twice daily (Tixteller(®)/Tixtar(®)) for the reduction of the recurrences of overt HE, with respect to the current treatment approach. PATIENTS AND METHODS: Costs associated with patients treated with rifaximin 550 mg twice daily were estimated considering the reduction in hospitalizations for HE recurrences revealed by registrative clinical trial (-50%) applied to the hospitalization rate (42...
2017: Hepatic Medicine: Evidence and Research
https://www.readbyqxmd.com/read/29020023/the-continuous-reaction-time-test-for-minimal-hepatic-encephalopathy-validated-by-a-randomized-controlled-multi-modal-intervention-a-pilot-study
#5
M M Lauridsen, S Mikkelsen, T Svensson, J Holm, C Klüver, J Gram, H Vilstrup, O B Schaffalitzky de Muckadell
BACKGROUND: Minimal hepatic encephalopathy (MHE) is clinically undetectable and the diagnosis requires psychometric tests. However, a lack of clarity exists as to whether the tests are in fact able to detect changes in cognition. AIM: To examine if the continuous reaction time test (CRT) can detect changes in cognition with anti-HE intervention in patients with cirrhosis and without clinically manifest hepatic encephalopathy (HE). METHODS: Firstly, we conducted a reproducibility analysis and secondly measured change in CRT induced by anti-HE treatment in a randomized controlled pilot study: We stratified 44 patients with liver cirrhosis and without clinically manifest HE according to a normal (n = 22) or abnormal (n = 22) CRT...
2017: PloS One
https://www.readbyqxmd.com/read/28994123/systematic-review-with-meta-analysis-rifaximin-for-the-prophylaxis-of-spontaneous-bacterial-peritonitis
#6
REVIEW
A Goel, U Rahim, L H Nguyen, C Stave, M H Nguyen
BACKGROUND: The primary and secondary prevention of spontaneous bacterial peritonitis (SBP) is recommended in high-risk patients with cirrhosis. Several studies evaluating the efficacy of rifaximin for SBP prophylaxis have yielded conflicting results. Rifaximin has the potential advantage of preventing bacterial overgrowth and translocation without the systemic side effects of broad-spectrum antibiotics. AIM: To evaluate the efficacy of rifaximin in the primary and secondary prevention of SBP...
October 9, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28988773/rifaximin-resistant-clostridium-difficile-strains-isolated-from-symptomatic-patients
#7
E Reigadas, P Muñoz-Pacheco, L Alcalá, M Marín, A Martin, E Bouza
BACKGROUND: Rifaximin has been proposed as an alternative treatment for specific cases of Clostridium difficile infection (CDI) and intestinal decontamination. Rifaximin-resistant C. difficile has occasionally been reported. Antibiotic susceptibility testing relies on anaerobic agar dilution (reference method), which is cumbersome and not routinely used. There is no commercial test for detection of resistance to rifaximin. OBJECTIVES: To assess resistance to rifaximin by C...
October 6, 2017: Anaerobe
https://www.readbyqxmd.com/read/28982166/emergence-of-rifampin-resistant-staphylococci-after-rifaximin-administration-in-cirrhotic-patients
#8
Ji Young Chang, Seong-Eun Kim, Tae Hun Kim, So-Youn Woo, Min Sun Ryu, Yang-Hee Joo, Ko Eun Lee, Jihyun Lee, Kang Hoon Lee, Chang Mo Moon, Hye-Kyung Jung, Ki-Nam Shim, Sung-Ae Jung
OBJECTIVES: Rifaximin, a poorly absorbed antibiotics, has gut-specific therapeutic effects. Although frequently prescribed to manipulate intestinal luminal bacterial population in various diseases, the possible induction of antibacterial cross-resistance to a target pathogen is a major concern in long-term rifaximin administration. We aimed to evaluate whether rifampin-resistant staphylococci could evolve after rifaximin treatment in cirrhotic patients. METHOD: A total of 25 cirrhotic patients who were administered rifaximin for the prevention of hepatic encephalopathy were enrolled...
2017: PloS One
https://www.readbyqxmd.com/read/28957971/process-and-outcome-of-fecal-microbiota-transplants-in-patients-with-recurrent-clostridium-difficile-infection-a-prospective-study
#9
Janice Walton, Denise Burns, Kay E Gaehle
The incidence of Clostridium difficile infection is on the rise worldwide, causing high mortality rates and costing patients, hospitals, and insurance companies millions of dollars annually. Fecal microbiota transplants successfully treat recurrent C. difficile infections unresponsive to standard pharmacologic treatment such as flagyl, vancomycin, or rifaximin. Evidence in the literature provided the foundation for the development and refinement of this fecal microbiota transplant protocol. During the initial phase of the project, the protocol included patient selection criteria, donor screening/selection, infection control, fecal processing and delivery, and patient pre and postprocedure education...
September 2017: Gastroenterology Nursing: the Official Journal of the Society of Gastroenterology Nurses and Associates
https://www.readbyqxmd.com/read/28944070/rifaximin-versus-norfloxacin-for-prevention-of-spontaneous-bacterial-peritonitis-a-systematic-review
#10
Gurpartap S Sidhu, Andrew Go, Bashar M Attar, Hemant R Mutneja, Shilpa Arora, Sanjay A Patel
AIM: The aim of this systematic review is to evaluate the efficacy and safety of rifaximin in the prophylaxis of spontaneous bacterial peritonitis (SBP) as compared with norfloxacin. METHODS: We searched MEDLINE, CINAHL, Google Scholar and Cochrane databases from inception to January 2017. Reference lists of articles as well as conference proceedings were manually screened. We included studies that recruited patients with cirrhosis and ascites who met the criteria for primary or secondary SBP prophylaxis as defined by the European Association for the Study of the Liver and American Association for the Study of Liver Diseases...
2017: BMJ Open Gastroenterology
https://www.readbyqxmd.com/read/28942590/conservative-treatment-of-acute-colonic-diverticulitis
#11
REVIEW
S T van Dijk, S J Rottier, A A W van Geloven, M A Boermeester
PURPOSE OF REVIEW: Since the treatment of acute diverticulitis has become more conservative over the last years, knowledge of conservative treatment strategies is increasingly important. RECENT FINDINGS: Several treatment strategies that previously have been imposed as routine treatment are now obsolete. Uncomplicated diverticulitis patients can be treated without antibiotics, without bed rest, and without dietary restrictions; and a selected group of patients can be treated as outpatients...
September 23, 2017: Current Infectious Disease Reports
https://www.readbyqxmd.com/read/28936910/modulation-of-the-gut-microbiota-a-focus-on-treatments-for-irritable-bowel-syndrome
#12
Lucinda A Harris, Noemi Baffy
Irritable bowel syndrome (IBS), which is characterized by recurrent abdominal pain and disordered bowel habits, is one of the most common functional bowel disorders. IBS is a substantial burden on both patient health-related quality of life and health care costs. Several pathophysiologic mechanisms have been postulated for the occurrence of IBS, including altered gastrointestinal motility, visceral hypersensitivity, changes in gut permeability, immune activation, gut-brain dysregulation, autonomic nervous system dysfunction, and changes in the gut microbiota...
September 22, 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/28936406/gut-microbiome-based-therapeutics-in-liver-cirrhosis-basic-consideration-for-the-next-step
#13
REVIEW
Hiroshi Fukui
Infections account for significant morbidity and mortality in liver cirrhosis and most are related to the gut microbiome. Fecal dysbiosis, characterized by an overgrowth of potentially pathogenic bacteria and a decrease in autochthonous non-pathogenic bacteria, becomes prominent with the progression of liver cirrhosis. In cirrhotic patients, disruption of the intestinal barrier causes intestinal hyperpermeability (i.e. leaky gut), which is closely related to gut dysmotility, dysbiosis and small intestinal bacterial overgrowth and may induce pathological bacterial translocation...
September 28, 2017: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/28933189/reply-rifampin-resistant-staphylococcus-aureus-bacteremia-in-a-patient-on-chronic-rifaximin
#14
Paul Lewis, Imran A Khan, Paras D Patel
No abstract text is available yet for this article.
September 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28932270/repeat-treatment-with-rifaximin-improves-irritable-bowel-syndrome-related-quality-of-life-a-secondary-analysis-of-a-randomized-double-blind-placebo-controlled-trial
#15
Brooks D Cash, Mark Pimentel, Satish S C Rao, Leonard Weinstock, Lin Chang, Zeev Heimanson, Anthony Lembo
BACKGROUND: Diarrhea-predominant irritable bowel syndrome (IBS-D) impairs patient quality of life (QOL). Rifaximin is an oral, nonsystemic antibiotic indicated for IBS-D. The objective of this secondary analysis was to evaluate rifaximin retreatment on IBS-related QOL in patients with IBS-D. METHODS: Patients received open-label rifaximin 550 mg three times daily for 2 weeks. Clinical responders [simultaneously meeting weekly response criteria for abdominal pain (⩾30% improvement from baseline in mean weekly pain score) and stool consistency (⩾50% decrease from baseline in number of days/week with Bristol Stool Scale (BSS) type 6 or 7 stools) during ⩾2 of first 4 weeks posttreatment] who relapsed during an up to 18-week treatment-free observation phase were randomly assigned to receive two 2-week courses of double-blind rifaximin or placebo, separated by 10 weeks...
September 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28913777/diabetes-and-the-small-intestine
#16
REVIEW
Jonathan Gotfried, Stephen Priest, Ron Schey
Diabetes mellitus (DM) and its associated complications are becoming increasingly prevalent. Gastrointestinal symptoms associated with diabetes is known as diabetic enteropathy (DE) and may manifest as either diarrhea, fecal incontinence, constipation, dyspepsia, nausea, and vomiting or a combination of symptoms. The long-held belief that vagal autonomic neuropathy is the primary cause of DE has recently been challenged by newer theories of disease development. Specifically, hyperglycemia and the resulting oxidative stress on neural networks, including the nitrergic neurons and interstitial cells of Cajal (ICC), are now believed to play a central role in the development of DE...
September 15, 2017: Current Treatment Options in Gastroenterology
https://www.readbyqxmd.com/read/28902040/long-term-rifaximin-therapy-as-a-primary-prevention-of-hepatorenal-syndrome
#17
El-Sayed Ibrahim, Ayman Alsebaey, Hassan Zaghla, Sabry Moawad Abdelmageed, Khalid Gameel, Eman Abdelsameea
BACKGROUND: Hepatorenal syndrome (HRS) is a severe complication of liver cirrhosis, with poor survival. Rifaximin is a gut-selective broad-spectrum antibiotic. AIM: The aim of this study was to evaluate the role of rifaximin as a primary prevention of HRS. PATIENTS AND METHODS: Eighty patients with liver cirrhosis and ascites were enrolled. They were randomized into two groups: control (n=40) and rifaximin group (n=40). Baseline liver function tests, renal function tests, complete blood count, international normalized ratio, urine analysis, and abdominal ultrasonography were carried out...
November 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28894393/review-of-rifaximin-latest-treatment-frontier-for-irritable-bowel-syndrome-mechanism-of-action-and-clinical-profile
#18
Kamesh Gupta, Harparam Singh Ghuman, Shivani Vijay Handa
BACKGROUND: Irritable bowel syndrome is classified as a functional gastrointestinal disorder with the primary symptom of abdominal pain in conjunction with bloating and bowel movement disorder. It affects up to 15% of the world's population. Among its subtypes, the most common is diarrhoea predominant. However, the current treatment options for diarrhoea-predominant irritable bowel syndrome have had not very promising results; most, such as antispasmodics, only provide partial symptomatic relief...
2017: Clinical Medicine Insights. Gastroenterology
https://www.readbyqxmd.com/read/28885920/antibiotic-therapy-for-acute-watery-diarrhea-and-dysentery
#19
David R Tribble
Diarrheal disease affects a large proportion of military personnel deployed to developing countries, resulting in decreased job performance and operational readiness. Travelers' diarrhea is self-limiting and generally resolves within 5 days; however, antibiotic treatment significantly reduces symptom severity and duration of illness. Presently, azithromycin is the preferred first-line antibiotic for the treatment of acute watery diarrhea (single dose 500 mg), as well as for febrile diarrhea and dysentery (single dose 1,000 mg)...
September 2017: Military Medicine
https://www.readbyqxmd.com/read/28884456/erratum-to-repeat-rifaximin-for-irritable-bowel-syndrome-no-clinically-significant-changes-in-stool-microbial-antibiotic-sensitivity
#20
M Pimentel, B D Cash, A Lembo, R A Wolf, R J Israel, P Schoenfeld
No abstract text is available yet for this article.
September 7, 2017: Digestive Diseases and Sciences
keyword
keyword
17795
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"